Table 1.
Characteristics of patients who were observed ALP flare during EGFR-TKI treatment.
| No. | Age | Sex | EGFR mutation | Bone metastasis | Baseline ALP | Peak ALP (day) | Baseline peak ratio | Peakout ALP (day) | Response | Total medication (day) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | F | 19 deletions | + | 783 | 1006 (8) | 1.28 | 319 (115) | PR | 185 |
| 2 | 60 | M | 21 L858R | + | 534 | 731 (9) | 1.36 | 316 (32) | PR | 174 |
| 3 | 68 | M | 21 L858R | unknown | 385 | 554 (28) | 1.43 | 293 (126) | PR | 196 |
| 4 | 74 | F | – | + | 362 | 538 (16) | 1.48 | 309 (44) | PR | 314 |
| 5 | 81 | F | 21 L858R | + | 291 | 548 (12) | 1.88 | 301 (40) | PR | 339 |
| 6 | 63 | M | 21 L858R | unknown | 530 | 1121 (18) | 2.11 | 298 (66) | PR | 119 |
| 7 | 60 | M | 21 L858R | + | 1324 | 3236 (15) | 2.44 | 1065 (55) | PR | 56< |
| 8 | 73 | M | 18 G719X | + | 842 | 1009 (7) | 1.2 | 350 (91) | PR | 182 |
| 9 | 73 | F | 19 deletions | – | 289 | 401 (101) | 1.39 | 321 (136) | PR | 986< |
| 10 | 80 | M | 19 deletions | + | 239 | 429 (15) | 1.79 | 238 (35) | PR | 255< |
| 11 | 71 | M | 19 deletions | + | 1012 | 1854 (21) | 1.83 | 318 (197) | PR | 226 |
No.1–7: gefitinib group, No.8–11: erlotinib group.